Subsidised access to TNF-alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
Mann
Erica L
EL
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology*; D001315:Australia; D015276:Health Care Rationing / Q000379:methods*; D006801:Humans; D009363:Neoplasm Proteins / Q000191:economics / Q000627:therapeutic use*; D018579:Patient Selection; D047889:Receptors, Tumor Necrosis Factor, Type II; D012217:Rheumatoid Factor / Q000097:blood*; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors
D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D012217:Rheumatoid Factor